Rhian Touyz, ISH President, Glasgow, UK
Posted on 23/09/2015
View the paper that Professor Rhian Touyz (ISH President based in the Institute of Cardiovascular and Medical Sciences at the University of Glasgow, UK) is reading right now.
Professor Rhian Touyz, ISH President, UK (pictured below)
Hypertension. 2015 Sep;66(3):543-9
Lankhorst S, Baelde HJ, Kappers MH, Smedts FM, Hansen A, Clahsen-van Groningen MC, Sleijfer S, Mathisjssen RH, Danser AH, van den Meiracker AH.
Hypertension and renal injury are off-target effects of sunitinib, a tyrosine kinase receptor inhibitor used for the treatment of various tumor types. Importantly, these untoward effects are accompanied by activation of the endothelin system. Here, we set up a study to explore the dose dependency of these side effects. Normotensive Wistar Kyoto rats were exposed to 3 different doses of sunitinib or vehicle. After 8 days, rats were euthanized. Telemetrically measured blood pressure rose dose dependently, from 13 to 30 mm Hg. Proteinuria was present at all doses, but a rise in cystatin C occurred only at the intermediate and high doses. Compared with vehicle circulating endothelin-1 increased dose dependently, whereas 24-hour urinary endothelin excretion decreased. Light and electron microscopy revealed glomerular endotheliosis and ischemia with the intermediate and high doses of sunitinib but completely absent histological abnormalities with the low dose. Podocyte number per glomerular circumference did not change. Glomerular nephrin, Neph1, podocin, and endothelin-converting enzyme gene expression were downregulated in a dose-dependent manner. We conclude that the sunitinib-induced rise in blood pressure requires lower doses than its induction of renal function impairment and that functional changes in glomerular filtration barrier contribute to the occurrence of proteinuria, given the lack of histopathologic changes with the low dose of sunitinib.